Plasma NfL levels could serve as a potential biomarker for neurodegeneration in the general population, helping to differentiate cognitive decline caused by AD from other conditions that lead to cognitive impairment during the prodromal stages in the general population [70]. Here, NEFL is linked to Alzheimer disease.